CEO Erik Kinnman will describe Abliva's operations, the background to the company's strategic direction and the name change (formerly NeuroVive).
Abliva's Chief Medical Officer, Magnus Hansson, and Matilda Hugerth, Director Clinical and Regulatory Affairs, will address the major medical needs in primary mitochondrial diseases, the benefits of the company's development projects being in the orphan drug field, and describe the plans and clinical developments for Abliva's key projects KL1333 and NV354..
Furthermore, Abliva's incoming board member Dr. Roger Franklin, who represents Hadean Ventures, new shareholder in Abliva, is interviewed. Hadean Ventures is a fund manager specializing in life science investments.
The program, moderated by Charlotte Stjerngren, ends with a question and answer session and studio discussion in which external analysts also participate as questioners. During the program it will be possible to ask questions to the company on email@example.com. The meeting will mostly be held in Swedish.
Abliva AB is the new name that replaces the former NeuroVive Pharmaceutical AB. The name change is part of the company's focus on primary mitochondrial diseases, all of which have high unmet medical needs and are orphan indications. Abliva's main projects, KL1333 and NV354, are both focused on primary mitochondrial diseases. The company's drug candidate NeuroSTAT, is planned to be placed in a separate wholly-owned company after undiluted financing is secured in order to give the project the best opportunities for resource allocation and further development to the market.
The Capital Markets Day will be followed via Abliva's website at: http://abliva.com/sv/investor/capital-markets-day-2020/. The recording will also be posted afterwards.
Questions can be asked to firstname.lastname@example.org.
Welcome on June 23rd!